rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Adicet Bio, Inc.

ACET · Nasdaq

Health CareBiotechnologyNot moving yet

ACET stood above a rising 150-day average in 9 of the last 52 weekly readings, and has been out of that trend for the last 4 weeks. It is 43.4% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−12 points in four weeks); Health Care: 28% (−6 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 4
Industry in uptrend
18% -12 in 4 wk
Insider buys, 12 months
$3.2M
Insider sales, 12 months
$1.3M
Officials’ trades on record
0
Institutions holding
54 (+11)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 9 of 52 weeks.

22 Apr – 21 Oct
16%27%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1.1M$0$4.8MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months6
Sale orders, 12 months4
Buyers · sellers2 · 2
WhoDidSharesTraded
Orbimed Advisors Llc10% ownersold32,523at $6.298 Apr 2026filed 9 Apr 2026
Orbimed Advisors Llc10% ownersold40,416at $6.528 Apr 2026filed 9 Apr 2026
Orbimed Advisors Llc10% ownersold29,319at $6.537 Apr 2026filed 9 Apr 2026
Orbimed Advisors Llc10% ownersold2,400at $6.387 Apr 2026filed 9 Apr 2026
Ra Capital Management, L.p.10% ownerbought74,751at $7.2720 Feb 2026filed 13 Apr 2026
Ra Capital Management, L.p.10% ownerbought74,268at $7.2119 Feb 2026filed 13 Apr 2026
Ra Capital Management, L.p.10% ownerbought74,577at $7.0418 Feb 2026filed 13 Apr 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders54+11 on the quarter
New · exited15 · 4
Reported value$51.7M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
RA CAPITAL MANAGEMENT, L.P.reduced · filed 14 Aug 2026932,624$8.1M-250,000−21.1%
ORBIMED ADVISORS LLCreduced · filed 14 Aug 2026844,787$7.3M-183,157−17.8%
FRANKLIN RESOURCES INCunchanged · filed 13 Aug 2026626,571$5.4M00.0%
CITADEL ADVISORS LLCadded · filed 14 Aug 2026432,738$3.7M+50,915+13.3%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026343,228$3.0M+6,704+2.0%
ADAGE CAPITAL PARTNERS GP, L.L.C.unchanged · filed 14 Aug 2026274,375$2.4M00.0%
RENAISSANCE TECHNOLOGIES LLCadded · filed 13 Aug 2026265,945$2.3M+33,354+14.3%
Stonepine Capital Management, LLCadded · filed 14 Aug 2026245,518$2.1M+23,563+10.6%
Alyeska Investment Group, L.P.unchanged · filed 14 Aug 2026203,799$1.8M00.0%
Schonfeld Strategic Advisors LLCnew · filed 14 Aug 2026195,514$1.7M+195,514
31 Dec 2025 – 30 Jun 2026
434954Dec 25Mar 26Jun 26

Everyone who traded it

Lloyd Klickstein Company insiderChief Medical Officer · last 5 Aug 20260 · 0
Andrew Sinclair Company insiderDirector · last 21 Jun 20262 · 0
Jeffrey Chodakewitz Company insiderDirector · last 21 Jun 20260 · 0
Katie Peng Company insiderDirector · last 21 Jun 20260 · 0
Michael Grissinger Company insiderDirector · last 21 Jun 20260 · 0
Steve Dubin Company insiderDirector · last 21 Jun 20261 · 0
Blake Aftab Company insiderChief Scientific Officer · last 19 Jun 20260 · 6
Chen Schor Company insiderPresident & CEO · last 19 Jun 20265 · 19
RA CAPITAL MANAGEMENT, L.P. Company insider10% owner · last 27 Apr 20263 · 0
Rajeev M. Shah Company insider10% owner · last 27 Apr 20260 · 0
Orbimed Advisors Israel Ii Ltd Company insider10% owner · last 8 Apr 20261 · 2
ORBIMED ADVISORS LLC Company insider10% owner · last 8 Apr 20262 · 2

Same industry

MRNA ModernaLeading+168%
ENTX Entera BioLeading+53%
XNCR XencorLeading+41%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-71.5%
Share count trendFY 2025 · to 10 Mar 20260.1%
Cash and equivalentsFY 2025 · to 31 Dec 2025$38.9M
Free cash flowFY 2025 · to 31 Dec 2025−$97.0M

Analyst forecasts

No analyst forecasts yet.